ライフサイエンスコーパス: torsade de pointes

1 nctive polymorphic ventricular tachycardia ('torsades de pointes').

2 ciated arrhythmias (eg, long QT syndrome and torsade de pointes).

3 ion of the QT interval and/or development of torsades de pointes).

4 y-high-dose methadone may be associated with torsade de pointes.

5 European market after being associated with torsade de pointes.

6 sion of atrial arrhythmias, but it can cause torsade de pointes.

7 o prolongs the QT interval but rarely causes torsade de pointes.

8 s, and thus the potential for development of torsade de pointes.

9 h from ventricular arrhythmias, specifically torsade de pointes.

10 interval and an increased propensity toward torsade de pointes.

11 to explain the link between hypokalemia and torsade de pointes.

12 at of antiarrhythmic agents known to promote torsade de pointes.

13 d is a significant predictor of drug-induced torsade de pointes.

14 may cause abnormal heart rhythms, including torsade de pointes.

15 gned to examine the risk of rare events like torsade de pointes.

16 load, early afterdepolarizations (EADs), and torsade de pointes.

17 T syndrome and the lethal cardiac arrhythmia torsade de pointes.

18 ype 2, women are more vulnerable than men to torsade de pointes.

19 QT prolongation with the associated risk of torsade de pointes.

20 redispose individuals to QT prolongation and torsade de pointes.

21 es, which are thought to trigger episodes of torsades de pointes.

22 f repolarization are not capable of inducing torsades de pointes.

23 ar tachycardia displaying characteristics of torsades de pointes.

24 ciated with the potentially fatal arrhythmia torsades de pointes.

25 ally the polymorphic ventricular tachycardia torsades de pointes.

26 duced long QT interval syndrome (diLQTS) and torsades de pointes.

27 lead to interventions to reduce the risk of torsades de pointes.

28 sociated with the rare adverse drug reaction torsades de pointes.

29 adverse events including QT prolongation and torsades de pointes.

30 to hyperfunction of L-type channels, such as Torsades de Pointes.

31 quired and drug-induced long QT syndrome and torsades de pointes.

32 ation and is associated with case reports of torsades de pointes.

33 enic afterdepolarizations thought to trigger torsades de pointes.

34 There was 1 episode of nonsustained torsade de pointes (1 of 70, 1.4%) after ibutilide.

35 16 cardiac arrests, with one resulting from Torsade de Pointes (6%).

36 enic can prolong the QT interval and lead to torsade de pointes, a life-threatening ventricular arrhy

37 Torsades de pointes, a form of ventricular tachycardia,

38 mary suspect in cases of QTc prolongation or torsade de pointes after dofetilide (a known proarrhythm

39 n in the placebo group (0.3% versus 0.1% for torsade de pointes and 0.9% versus 0.2% for severe neutr

40 The incidences of torsade de pointes and severe neutropenia (absolute neut

41 Prediction of torsade de pointes and sudden death can be improved by e

42 iew the mechanisms and establish the risk of torsade de pointes and sudden death with antipsychotic d

43 nd haloperidol have been documented to cause torsade de pointes and sudden death, the most marked ris

44 cognition of the role of noncardiac drugs in torsade de pointes and sudden death.

45 Another developed sustained torsade de pointes and was treated effectively with dire

46 Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, a

47 ssociated with complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block

48 On the other hand, drug-induced torsades de pointes and symptomatic long QT syndrome hav

49 ments, can result in ventricular arrhythmia (torsade de pointes) and sudden death.

50 eads to polymorphic ventricular tachycardia (torsades de pointes) and sudden death.

51 ncope, polymorphous ventricular tachycardia (torsades de pointes), and sudden arrhythmic death.

52 clinical use is burdened by QT prolongation, torsade de pointes, and sudden cardiac death.

53 n between familial and drug-induced cases of torsade de pointes, and the recognition of the role of n

54 Cases of QT prolongation, torsades de pointes, and sudden death have been reported

55 QT interval prolongation and torsade de pointes are associated with astemizole intake

56 0400 is effective against dofetilide-induced torsade de pointes arrhythmias (TdP), while maintaining

57 Torsade de pointes arrhythmias could be induced during e

58 interval on the electrocardiogram and cause torsade de pointes arrhythmias not by direct block of th

59 is commonly associated with life-threatening torsade de pointes arrhythmias that develop as a consequ

60 ties that have been associated with syncope, torsade de pointes arrhythmias, and sudden cardiac death

61 nterval and predispose to the development of torsade de pointes arrhythmias.

62 el are associated with an increased risk for Torsades des Pointes arrhythmias and sudden death.

63 ontractions and fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit sever

64 se in the intracellular calcium may underlie torsades de pointes associated with intravenous tacrolim

65 that infrequently causes QT-prolongation and torsades de pointes cardiac arrhythmias.

66 lt to predict which patients are at risk for torsade de pointes, careful assessment of the risk to be

67 ENDO, causing a persistent increase in TDR; Torsade de Pointes developed or could be induced only in

68 bradycardia per se, determines the risk for torsade de pointes during atrioventricular block (AVB).

69 nd Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolongin

70 ated in causing QT interval prolongation and torsades de pointes, errors in the use of medications th

71 clinical observation of QT prolongation and torsade de pointes found with astemizole intake may prin

72 They examine the risk for torsade de pointes from antipsychotic drugs and estimate

73 terval prolongation, potassium channels, and torsade de pointes from both the long QT syndrome and dr

74 ars, and cases of prolonged QTc interval and torsades de pointes have been described in HIV-infected

75 arrhythmias developed in 7 patients (5.8%) (torsade de pointes in 2), significant bradycardia in 20

76 clinical observation of QT prolongation and torsade de pointes in a patient with undetectable serum

77 was a significant predictor of drug-induced torsade de pointes in an independent sample of 216 cases

78 APD(90,) reduced BVR (P<0.01), and abolished torsade de pointes in hearts treated with either 20 nmol

79 o the cell surface cause QT prolongation and torsade de pointes in patients treated with As(2)O(3).

80 , which has been recognized as a hallmark of torsade de pointes in the acquired LQTS, plays a major r

81 to describe the mode of onset of spontaneous torsade de pointes in the congenital long QT syndrome.

82 The in vivo electrophysiologic mechanism of torsade de pointes in the long QT syndrome is described,

83 ervals and higher incidences of drug-induced torsade de pointes in women than in men are incompletely

84 eats after aftercontractions occurred before torsades de pointes in an in vivo dog model of drug-indu

85 s used to examine susceptibility to acquired torsades de pointes in chronic atrioventricular block an

86 voke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.

87 proved predictors of risk for progression to torsade de pointes, in addition to the degree of QT prol

88 ing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intr

89 Monthly reports of QTc prolongation or torsade de pointes increased from a mean of 0.3 (95% CI,

90 A common effect of many drugs producing torsade de pointes is block of the rapidly activating co

91 ion of the QT interval and the occurrence of torsades de pointes is similar to more expensive alterna

92 The progression to torsade de pointes may be less related to degree of QT p

93 cially amiodarone, and drugs associated with torsade de pointes may have contributed to poor outcomes

94 dult gender differences in propensity toward torsade de pointes may reflect the relatively greater pr

95 over, the data suggest that cisapride caused torsade de pointes not only by blocking IKr but also by

96 Torsade de pointes occurred after an abrupt acceleration

97 Two cases of torsade de pointes occurred, 1 on day 2 and the other on

98 longation after ibutilide, only 1 episode of torsade de pointes occurred.

99 /31; 61%) versus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1

100 Torsade de pointes often occurs with underlying hypokale

101 nic atrioventricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was in

102 is no evidence to suggest that this leads to torsade de pointes or sudden death.

103 None of the patients on sotalol developed Torsade de pointes or sustained ventricular arrhythmias.

104 entified 24 patients with QT prolongation or torsade de pointes, or both, associated with protease in

105 entricular tachycardia, ventricular flutter, torsade de pointes, or ventricular fibrillation.

106 netheless, drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians

107 en identified in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisap

108 All drugs that cause torsade de pointes prolong the QTc interval and bind to

109 g class IC drugs, patients with low risk for torsades de pointes receiving selected class III agents,

110 The patient suffered recurrent runs of torsade de pointes, refractory to aggressive medical man

111 Drug-induced QT prolongation and torsades de pointes remain significant and often unpredi

112 ind QT prolongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardia

113 icited seizure was followed by an episode of torsade de pointes requiring immediate cardioversion.

114 A set of drugs with known clinical torsade de pointes risk was selected to develop and cali

115 l prolongation in hospitalized patients with torsades de pointes risk factors.

116 The risk of torsades de pointes should be assessed in patients who a

117 rhythmic agent with the propensity to induce torsades de pointes, substantially inhibits the current.

118 5 micromol/L totally suppressed spontaneous torsade de pointes (TdP) and reduced the vulnerable wind

119 or inherited and acquired long-QT associated torsade de pointes (TdP) arrhythmias, and sympathetic di

120 e market because of its propensity to induce torsade de pointes (TdP) arrhythmias.

121 Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3

122 tricular tachycardia with characteristics of torsade de pointes (TdP) developed in the presence of dl

123 hat women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients

124 Female rabbit hearts are more susceptible to torsade de pointes (TdP) in acquired long QT type 2 than

125 functional electrical instability leading to torsade de pointes (TdP) in LQTS are poorly understood.

126 repolarization (TDR) and the development of Torsade de Pointes (TdP) in models of LQT1, LQT2 and LQT

127 ation (TDR) may be related to the genesis of torsade de pointes (TdP) in patients with the long-QT (L

128 ural dispersion of repolarization (TDR), and torsade de pointes (TdP) induced by beta-adrenergic agon

129 Drug-related torsade de pointes (TdP) is usually recognized within da

130 The ventricular arrhythmia torsade de pointes (TdP) occurs after QT interval prolon

131 ationary reentry, giving rise to the typical torsade de pointes (TDP) pattern.

132 ion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the

133 rigins of EADs and the mechanisms underlying Torsade de Pointes (TdP) were investigated in a model of

134 Extrasystolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimul

135 ion (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by

136 that the calmodulin inhibitor W-7 suppresses torsade de pointes (TdP) without shortening the QT inter

137 iac repolarization and increases the risk of Torsade de Pointes (TdP), a potentially lethal arrhythmi

138 SIDS), one with documented prolonged QTc and Torsade de Pointes (TdP), and in an adult woman with QTc

139 llation population despite its known risk of Torsade de pointes (TdP).

140 ngation yet absent proarrhythmia markers for Torsade de Pointes (TdP).

141 h a twisting QRS morphology, better known as torsade de pointes (TdP).

142 and to be associated with the development of torsade de pointes (TdP).

143 ntially life-threatening arrhythmia known as Torsade de Pointes (TdP).

144 Torsades de pointes (TdP) +/-2 degrees atrioventricular

145 cteristic of long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricu

146 healthy subjects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypo

147 teria that are associated with initiation of torsades de pointes (TdP) in patients with acquired (a-)

148 oal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associat

149 e used for AF, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinu

150 factors associated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.

151 eed for dose adjustment and the incidence of torsades de pointes (TdP) were identified.

152 a higher risk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.

153 oth syndromes can result in life-threatening torsades de pointes (TdP).

154 safety, including the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concer

155 Women have a higher incidence of torsades de pointes than men, but it is not known if the

156 QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of info

157 een shown to correlate with a higher risk of torsades de pointes, there is no established threshold b

158 creates the substrate for the development of torsade de pointes under long-QT conditions.

159 it is not known if the risk of drug-induced torsades de pointes varies during the menstrual cycle.

160 Torsade de pointes ventricular tachyarrhythmia in the lo

161 on of the action potential and propensity to torsade de pointes ventricular tachycardia.

162 There were no cases of torsades de pointes, ventricular fibrillation, or polymo

163 Twelve documented cases of torsade de pointes VT were noted.

164 sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of

165 The incidence of torsade de pointes was 0.6% at five years (95% confidenc

166 Documentation of the onset of torsade de pointes was available for 15 patients.

167 Pause-dependent torsade de pointes was clearly documented in 14 of the 1

168 iac death was recorded in five patients, and torsade de pointes was recorded in seven other patients.

169 When a drug associated with torsades de pointes was prescribed to a patient at moder

170 ons occurred due to QTc prolongation, and no Torsades de Pointes was reported.

171 arrest and 379 cases of QTc prolongation or torsade de pointes were associated with methadone.

172 ent with relapsed APL developed asymptomatic torsade de pointes, which resolved spontaneously and did

173 The characteristic association of torsade de pointes with T-wave alternans and short-long

174 ly fatal polymorphic ventricular tachycardia torsade de pointes, with drugs or other environmental st